Truist analyst Danielle Brill raised the firm’s price target on Neurocrine (NBIX) to $155 from $140 and keeps a Buy rating on the shares. Both Ingrezza and Crenessity sales exceeded the firm’s expectations for the quarter, and the set-up for Neurocrine is improving as base business outlook appears solid, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $246 from $242 at Citi
- Neurocrine price target raised to $207 from $190 at Piper Sandler
- Neurocrine price target raised to $191 from $185 at Morgan Stanley
- Neurocrine price target raised to $230 from $220 at Oppenheimer
- Neurocrine price target raised to $155 from $140 at Truist